Furthermore, several anti-PD-1 and PD-L1(B7-H1) antibodies have been approved for the treatment of an array of cancer types by The United States Food and Drug Administration (FDA), e.g., nivolumab (2014), pembrolizumab (2014), atezolizumab (2016), avelumab (2017), durvalumab (2017), cemiplimab (2018), dostarlimab (2021). The gene discussed is CD274; the disease is cancer.